J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

Potential For Post-Tagrisso Therapy Niche

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

lung illustration
J&J gets FDA speedy FDA approval for Rybrevant in non-small cell lung cancer with EGFR exon 20 insertion mutation • Source: Shutterstock

Johnson & Johnson is expected to aggressively promote Rybrevant (amivantamab-vmjw) following the US Food and Drug Administration’s rapid approval of the drug for a rare subset of non-small cell lung cancer (NSCLC). While Rybrevant may also have a place among NSCLC patients relapsing on AstraZeneca PLC’s Tagrisso (osimertinib), its safety and tolerability profile may place limitations on its uptake, potentially creating an opening for a competing drug in earlier development by Cullinan Oncology, Inc..

The FDA granted accelerated approval of Rybrevant on 21 May for locally advanced or metastatic NSCLC with EGFR exon 20...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer